BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 16288027)

  • 1. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.
    Yokoi K; Kim SJ; Thaker P; Yazici S; Nam DH; He J; Sasaki T; Chiao PJ; Sclabas GM; Abbruzzese JL; Hamilton SR; Fidler IJ
    Neoplasia; 2005 Jul; 7(7):696-704. PubMed ID: 16026649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
    Yokoi K; Thaker PH; Yazici S; Rebhun RR; Nam DH; He J; Kim SJ; Abbruzzese JL; Hamilton SR; Fidler IJ
    Cancer Res; 2005 May; 65(9):3716-25. PubMed ID: 15867367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
    Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
    Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.
    Kuwai T; Nakamura T; Sasaki T; Kitadai Y; Kim JS; Langley RR; Fan D; Wang X; Do KA; Kim SJ; Fidler IJ
    Clin Exp Metastasis; 2008; 25(4):477-89. PubMed ID: 18324358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
    Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
    Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
    Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
    Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
    Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
    Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
    Sasaki T; Kitadai Y; Nakamura T; Kim JS; Tsan RZ; Kuwai T; Langley RR; Fan D; Kim SJ; Fidler IJ
    Neoplasia; 2007 Dec; 9(12):1066-77. PubMed ID: 18084614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
    Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
    J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN
    Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
    Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
    Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.